Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 128 results for epilepsy

  1. MT650 24/7 EEG SubQ for people with epilepsy

    Topic prioritisation

  2. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy Interventional procedures guidance

    Question MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy Interventional procedures guidance Any explanatory...

  3. Transient loss of consciousness ('blackouts') in over 16s (QS71)

    This quality standard covers assessing, diagnosing and referring people (aged 16 and over) who have had a transient loss of consciousness (often called a blackout). It describes high-quality care in priority areas for improvement.

  4. Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

    Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Lennox–Gastaut syndrome in people aged 2 years and older.

  5. Epicranial focal cortex stimulation for drug-resistant focal epilepsy

    Topic prioritisation

  6. Transcranial direct current stimulation (tDCS) for the treatment of refractory epilepsy

    Topic prioritisation

  7. Digital health technologies: What is the clinical and cost effectiveness of digital health technologies in people with epilepsy?

    clinical and cost effectiveness of digital health technologies in people with epilepsy? Any explanatory notes(if applicable) For a short...

  8. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  9. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

  10. Contraception: advice for people taking anti-seizure medication (IND78)

    This indicator covers the percentage of women under the age of 55 years who are taking antiseizure medications who have a record of information and counselling about contraception, conception and pregnancy in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM03

  11. Vagus nerve stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a subgroup)?

    stimulation: What is the effectiveness of vagus nerve stimulation in treating epilepsy (including people with learning disabilities as a...

  12. Ketogenic diets: What is the short-term and long-term clinical and cost effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance and tolerability of ketogenic diets?

    effectiveness of ketogenic diets in adults and children with drug-resistant epilepsy, and what factors affect the long-term maintenance...

  13. Monitoring antiseizure medications in women and girls: What is the clinical and cost effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy?

    effectiveness of therapeutic drug monitoring in girls, young women and women with epilepsy? Any explanatory notes(if applicable) For a...

  14. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

  15. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC